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http://www.biosignaling.com/content/10/1/18RESEARCH Open AccessThe scaffold protein MEK Partner 1 is required for
the survival of estrogen receptor positive breast
cancer cells
Mihaela Marina1,2*, Limin Wang3 and Susan E Conrad3Abstract
MEK Partner 1 (MP1 or MAPKSP1) is a scaffold protein that has been reported to function in multiple signaling
pathways, including the ERK, PAK and mTORC pathways. Several of these pathways influence the biology of breast
cancer, but MP1’s functional significance in breast cancer cells has not been investigated. In this report, we
demonstrate a requirement for MP1 expression in estrogen receptor (ER) positive breast cancer cells. MP1 is widely
expressed in both ER-positive and negative breast cancer cell lines, and in non-tumorigenic mammary epithelial cell
lines. However, inhibition of its expression using siRNA duplexes resulted in detachment and apoptosis of several
ER-positive breast cancer cell lines, but not ER-negative breast cancer cells or non-tumorigenic mammary epithelial
cells. Inhibition of MP1 expression in ER-positive MCF-7 cells did not affect ERK activity, but resulted in reduced Akt1
activity and reduced ER expression and activity. Inhibition of ER expression did not result in cell death, suggesting
that decreased ER expression is not the cause of cell death. In contrast, pharmacological inhibition of PI3K signaling
did induce cell death in MCF-7 cells, and expression of a constitutively active form of Akt1 partially rescued the cell
death observed when the MP1 gene was silenced in these cells. Together, these results suggest that MP1 is
required for pro-survival signaling from the PI3K/Akt pathway in ER-positive breast cancer cells.
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The small protein MEK Partner 1 (MP1, also known as
Map Kinase Scaffold Protein 1 and LAMTOR3) was ori-
ginally identified as a scaffold protein that potentiates
MAPK signaling by binding to MEK1 and ERK1 [1].
MP1 interacts with another small protein p14, and to-
gether these two proteins are localized to endomem-
brane compartments as part of larger signaling
complexes. For example, an MP1-p14-MEK1 complex is
localized to late endosomes, and this localization is
required for EGF-induced ERK1/2 signaling [2-4]. A sec-
ond MP1-p14-p18 Ragulator complex is required for the
recruitment of mTORC1 to the lysosomal surface, and is
essential for amino acid-dependent signaling [5]. In* Correspondence: mihaela.marina@emory.edu
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reproduction in any medium, provided the oraddition to these trimeric complexes, MP1 has been
reported to bind PAK1 at the plasma membrane, and the
MP1-PAK1 interaction is required for MEK phosphoryl-
ation by PAK1 in the absence of Raf [6,7]. Thus, MP1
can regulate the function of several intracellular kinases
in different subcellular locations.
Both in vitro and in vivo approaches have been taken
to investigate the biological functions of MP1. Transient
inhibition of its expression using RNA interference in
fibroblasts resulted in decreased Rho activity and
delayed cell spreading on fibronectin [7], and similar
knockdown experiments in DU145 prostate cancer cells
resulted in decreased migration on fibronectin [8]. The
effect on migration was independent of MP1’s ability to
activate ERK and PAK1, since the levels of phosphory-
lated ERK and PAK1 were unchanged upon MP1 knock-
down. However, MP1 gene silencing in prostate cancer
cells was associated with both decreased expression of
paxillin and decreased number and turnover of focal
adhesions at the migratory edge. Taken together, theseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and















































Figure 1 MP1 expression in breast cancer cell lines. Human
mammary epithelial cell lines were grown in exponential culture and
whole-cell lysates were prepared. Top panel: Immunoblot from a
representative experiment. Lower panel: Quantitation of MP1/Actin
ratios in three independent experiments (mean ± SD, *p< 0.05). For
comparing groups of cell lines, an unpaired two-tailed evaluation
was done.
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related to cell spreading and migration.
Studies performed in conditional p14 knockout mice
and in Drosophila have addressed the in vivo functions
of MP1. The endosomal p14-MP1-MEK1 complex is
required for cell proliferation in the epidermis during
mouse embryogenesis [2]. In Drosophila, the MP1/ERK
complex regulates cell differentiation during develop-
ment of the wing, since both down-regulation and over-
expression of dMAPKSP1 led to an ectopic wing vein
phenotype [9]. In summary, MP1 is a widely expressed
protein that interacts with multiple protein kinases and
may impact various cellular processes including prolif-
eration, spreading, migration, and differentiation.
Many of the pathways and processes in which MP1
has been implicated play important roles in cancer biol-
ogy, including breast cancer. Breast cancer is the most
common type of cancer and the second most common
cause of death from cancer in women in the United
States [10]. A majority of breast tumors express estrogen
receptor alpha (ER) and depend on estrogen to grow
[11]. There is extensive cross-talk between ER and other
cellular signaling pathways, including those in which
MP1 functions [12-14]. We therefore hypothesized that
MP1 might play an important role in ER-positive breast
cancer cells. To test this hypothesis, we analyzed MP1
expression and function in a panel of tumorigenic and
non-tumorigenic human mammary epithelial cell lines.
Immunoblotting experiments demonstrated that MP1
protein is expressed in both ER-positive and ER-negative
breast cancer cell lines, as well as in non-tumorigenic
cells. However, the effects of inhibiting MP1 expression
by transient transfection with siRNA duplexes differed
between different cell types. MP1 gene silencing induced
apoptosis of three ER-positive breast cancer cell lines,
including one with acquired endocrine resistance. In
contrast, no cell death was observed in ER-negative
breast cancer or non-tumorigenic cell lines. The apop-
tosis observed in ER-positive cells was associated with
cell detachment, and with decreased ER expression and
Akt activity. The cell death phenotype could be partially
reversed by overexpressing a constitutively active form
of Akt1, suggesting that MP1 plays a novel role in pro-
moting survival of ER-positive breast cancer cells at least
in part via the Akt pathway.
Results
MP1 protein expression in human mammary epithelial
cells
MP1 protein expression levels were assessed by immu-
noblotting in the following human mammary epithelial
cell lines: MCF10A and 184B5 (nontumorigenic), MCF-7,
MCF-7/LCC9 (LCC9), T47D, and ZR-75-1 (tumorigenic,
ER-positive), and MDA-MB-231, BT-549, Hs579T, andSk-Br-3 (tumorigenic, ER-negative) (Figure 1). MP1 was
present in all cell lines, although the level was variable.
Actin expression also varied between cell lines, but was
consistent between experiments. A comparison between
the three categories of cell lines indicated significantly
higher levels of MP1 protein in the ER-positive breast
cancer cells than in ER-negative breast cancer or non-
tumorigenic cell lines.
Since the number of cell lines investigated was limited,
we also queried publicly available breast tumor databases
for MP1 mRNA expression as described in the methods
section. Briefly, eight independent datasets were com-
bined, resulting in a single dataset containing 1459 sam-
ples. Batch effects were removed using the BFRM
algorithm, and MP1 expression levels were examined. In
agreement with the protein results, MP1 mRNA was
expressed in both ER positive and negative tumors, but
showed a statistically significant elevation in samples
that were scored either ER+/PR+ or ER+/PR- by
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Since not all of the samples in the combined dataset were
scored for ER and PR, we predicted ER/PR status in the
entire dataset using genomic signatures as previously
described [15], and compared MP1 levels in ER/PR posi-
tive vs. negative tumors. This analysis also indicated that
MP1 mRNA is expressed in both groups, but is present
at higher levels in ER/PR positive tumors (p< 0.001).
One clinical study identified MP1 as a gene associated
with a poor prognosis signature in sporadic lymph-node
negative breast cancer patients [16], but in our analysis
high MP1 expression was not correlated with either time
to distant metastasis or disease free survival.CON siRNA MP1  siRNA #1 MP1A





Figure 2 MP1 expression is required for attachment and survival of E
control or MP1 siRNAs as described in Materials and Methods. At 48 h cells
preparation. (A) Photographs of MCF-7 cells transfected with two different
Immunoblots of extracts prepared from cells shown in panel (A). Numbers
LCC9 and T47D cells transfected with MP1 siRNA or control siRNA. Scale ba
panel (C). (E) Attached and floating cells were collected and analyzed as de
bars) and live cells (white bars) in each population was determined by tryp
independent experiments. Upper error bars indicate the SD for dead cells aInhibition of MP1 expression induces cell death and
detachment of ER-positive breast cancer cells
To study the effect of inhibiting MP1 expression in
breast cancer cells, short interfering RNA (siRNA)
duplexes were used. Initial experiments were carried out
in ER-positive MCF-7 cells. By 48 h post-transfection,
cells treated with either of two independent MP1 siR-
NAs displayed a dramatic phenotype involving cell
rounding and detachment (Figure 2A), and by 72 h vir-
tually all cells had detached from the plates (not shown).
As shown in Figure 2B, MP1 protein levels were reduced
more than 50% with these two MP1 siRNAs relative to
control siRNA. To determine if the response to MP1  siRNA #2
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R-positive breast cancer cells. Cells were transfected with 40 nM
were photographed, then harvested for counting and extract
MP1 siRNA and control siRNA sequences. Scale bar = 100 μm (B)
represent the relative MP1/Actin ratios. (C) Photographs of MCF-7,
r = 100 μm. (D) Immunoblots of extracts prepared from cells shown in
scribed in Materials and Methods. The percentage of dead cells (black
an blue exclusion assays. Data represents the mean ± SD of three
nd lower error bars represent the SD for live cells.
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cells, two additional ER-positive cell lines were exam-
ined: LCC9 and T47D. The LCC9 cell line is an estrogen
independent and antiestrogen resistant derivative of
MCF-7 cells [17], and T47D is an independently derived
ER-positive cell line. MP1 siRNA #1 was used in these
experiments. As shown in Figure 2C, both LCC9 and
T47D cells exhibited a phenotype similar to MCF-7. To
quantitate the effect of MP1 silencing, attached and
detached cells were collected at 48 h following siRNA
transfection, stained with trypan blue, and counted. As
shown in Figure 2E, MCF-7 cells were the most sensitive
to MP1 knockdown. More than 70% of MCF-7 cells had
detached by 48 h, and the majority of these were dead as
determined by trypan blue staining. In contrast, only
10% of cells were detached in the control siRNA trans-
fections. Both LCC9 and T47D cells also showed a sig-
nificant increase in dead/floating cells upon MP1
silencing, with the average percentage of dead cells at
48 h being 70% for MCF-7, 42% for LCC9 and 49% for
















Figure 3 MP1 expression is not required for attachment or survival o
40 nM control or MP1 siRNAs for all cell lines except 184B5, where 150 nM
cells were photographed, then harvested for counting and extract prepara
184B5 cells. Scale bar = 100 μm. (B) Immunoblots of transfected samples. N
trypan blue exclusion assays were carried out as described in the legend to
experiments for all samples except 184B5 cells. For this cell line the numberequired for the survival of ER-positive breast cancer cell
lines, including one with acquired endocrine resistance.
Inhibition of MP1 expression does not induce death of
ER-negative breast cancer cells or non-tumorigenic cells
Since MP1 is also expressed in ER-negative breast cancer
cells and in non-tumorigenic mammary epithelial cells
(Figure 1), the effect of MP1 silencing in representatives
of these cell types was also examined. Three ER-negative
breast cancer cell lines (MDA-MB-231, BT-549, and Sk-
Br-3) and one non-tumorigenic mammary epithelial cell
line (184B5) [18] were transfected with either control or
MP1 siRNA and examined at 48 h. Although MP1 levels
were decreased to the same or greater extent as observed
in the ER-positive cell lines, no obvious changes in cell
morphology were seen, and cell counting/trypan blue ex-
clusion assays indicated that there was no significant in-
crease in cell detachment or death in compared to
control cells (Figure 3). Thus, within this sample, the re-
quirement for MP1 expression for cell attachment and
survival was specific to ER-positive breast cancer cells./Actin    100    19     100      40       100     39      100      18      
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MDA-MB-231 BT-549 Sk-Br-3 184B5
dead cells
live cells
f ER-negative mammary epithelial cells. Cells were transfected with
siRNAs were used, as described in Materials and Methods. At 48 h
tion. (A) Photographs of transfected MDA-MB-231, BT-549, Sk-Br-3, and
umbers represent the relative MP1/Actin ratios. (C) Cell counting and
Figure 2. Error bars represent the mean ± SD of three independent
rs shown represent the average of two independent experiments.
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MCF-7 cells
To determine if the cell death observed upon MP1 silen-
cing in MCF-7 cells was due to apoptosis, several markers
of apoptosis were examined. As shown in Figure 4A, ex-
pression of the anti-apoptotic protein Bcl-2 decreased
more than two fold in cells treated with MP1 siRNA for
48 h. There was also a small decrease in Bcl-2 expression
at 24 h, but knockdown of MP1 expression was not always
detected at this time point, so most analyses were done at
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Figure 4 MP1 silencing induces apoptosis of MCF-7 but not of MDA-M
48 h with 30 nM control or MP1 siRNA. (A) Immunoblot of Bcl-2 protein le
expressed as percentage of control samples for a single experiment (24 h)o
Immunoblot of PARP in extracts of MCF-7 and MDA-MB-231 cells at 48 h. (
Annexin V and propidium iodide, and analyzed by flow cytometry as descr
the percentage of cells that are PI-/Annexin- (lower left), PI+/Annexin- (upp
immunoblot of MP1 expression is also shown. (D) Photographs of MCF-7 c
z-VAD-FMK at 48 h. Scale bar = 100 μm. (E) Immunoblot and quantificationof poly (ADP-ribose) polymerase (PARP), which is a
marker of apoptosis, occurred in MP1 siRNA treated
MCF-7 cells but not MDA-MB-231 cells (Figure 4B).
Consistent with these data, there was a dramatic in-
crease in annexin V-positive apoptotic cells, from 7% to
27%, as a result of MP1 silencing (Figure 4C). To fur-
ther confirm that MCF-7 cell death was via apoptosis,
cells were treated with the pan-caspase inhibitor z-VAD-
FMK concurrently with siRNA transfection. As shown
in Figures 4D and 4E, this treatment prevented cell
rounding/detachment and PARP cleavage in MCF-7 cells.MCF-7
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siRNA      CON   MP1  MP1
E
Actin
% cleaved PARP 32      86     34         
100 24MP1/Actin
B-231 cells. MCF-7 or MDA-MB-231 cells were transfected for 24 or
vels in extracts of MCF-7 cells. Numbers represent the Bcl-2/Actin ratios
r the average ± SD of 3 independent experiments (48 h, p< 0.05). (B)
C) Transfected MCF-7 cells were harvested at 48 h, stained with
ibed in the methods section. Numbers in the 4 quadrants represent
er left), PI-/Annexin+ (lower right) and PI+/Annexin+ (upper right). The
ells transfected with MP1 siRNA in the absence or presence of 50 μM
of PARP cleavage at 48 h under the indicated conditions.
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decreases Akt activity but does not impact ERK
expression or activity in MCF-7 cells
To identify pathways affected by MP1 silencing, expres-
sion of total and phosphorylated ERK and Akt1 were
examined (Figure 5). Akt1 is a pro-survival protein with
a well-established role in the biology of cancer. ERK is
typically associated with proliferation, but may also be
involved in regulating cell survival. The level of phospho-
ERK was unaffected by MP1 knockdown (Figure 5A),
suggesting that a loss of ERK signaling is not responsible
for the cell detachment and death observed. In contrast,
phospho-Akt1 levels were decreased at both 24 and 48 h
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Figure 5 Effect of MP1 knockdown on cellular signaling pathways. MC
48 h. (A) Immunoblot of total and phosphor-ERK. The p-ERK/total ERK ratio
experiment (24 h) or as the average ± SD of 3 independent experiment
of p-Akt/total Akt are expressed as described for panel A. The ratios for the
(p< 0.05). (C) Immunoblot of ER at 48 h (n = 3 ± SD, p< 0.05). (D) Silencing
extracts were prepared at 48 h. Immunoblots of PARP, ER, MP1, and actin ar
were co-transfected with ERE-tk 109-luc and pβgal-Basic, then with control
of luciferase activity in the presence of CSS was set at 1 in each experiment
value. The results shown represent the average ± SD of 4 independent expesilencing on both ER expression and activity were also
examined. As shown in Figures 5C and 5E, both ER levels
and ER activity on an ERE-Luc reporter gene decreased
2–3 fold in MP1 siRNA treated cells. To determine if
decreased ER levels were responsible for the apoptosis
observed, the effects of silencing the ER gene alone or in
combination with the MP1 gene were examined. Silen-
cing of ER did not result in apoptosis of MCF-7 cells, in-
dicating that decreased ER expression alone is not the
cause of apoptosis in MP1 siRNA treated cells
(Figure 5D). In addition silencing ER did not prevent
apoptosis induced by MP1 silencing, suggesting that ER
expression itself is not required for the apoptotic
response.siRNA     CON  MP1
ER
Actin
ER/Actin  100  23±20   
MP1
C
00   57       100    42±16  
24h              48h
ON   MP1   CON   MP1




F-7 cells were transfected with 30 nM control or MP1 siRNA for 24 or
s are expressed relative to the ratio in control samples in a single
s (48 h) (p> 0.1). (B) Immunoblot of total and phospho-Akt. Ratios
48 h time point are the average ± SD of 4 independent experiments
of MP1 and ER. Cells were transfected with the indicated siRNAs, and
e shown. (E) Quantification of luciferase activity in MCF-7 cells. Cells
or MP1 siRNA and treated with medium containing CSS ± E2. The level
, and the activity in E2 treated samples was expressed relative to this
riments. (*p< 0.05).
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of MCF-7 and MDA-MB-231 cells
Inhibition of MP1 expression resulted in cell death in
MCF-7 cells, and this was correlated with decreased
phosphorylated (active) Akt1 (Figure 5B). In contrast,
MDA-MB-231 cells showed no increase in cell death in
response to MP1 knockdown. If decreased Akt activity is
responsible for the cell death observed after MP1 knock-
down in MCF-7 cells, the lack of death in MDA-MB-
231 cells could be due to the fact that Akt activity is not
dependent on MP1 in MDA-MB-231 cells, or that sur-
vival of these cells is not dependent upon active Akt. To
test the latter possibility, MCF-7 and MDA-MB-231 cells
were treated with various concentrations of the PI3K in-
hibitor LY294002, and the effects on Akt1 phosphoryl-
ation and cell viability were examined. As shown in
Figure 6A, a concentration of 20 μM was sufficient to




























Figure 6 The PI3K/Akt pathway is required for survival of
MCF-7 but not MDA-MB-231 cells. MCF-7 and MDA-MB-231 cells
were treated with various concentrations of LY294002 for 48 h. (A)
Immunoblot of p-Akt in MCF-7 and MDA-MB-231 cells treated with
LY294002. (B) Effects of LY294002 treatment on viability as
determined by trypan blue exclusion assays (n = 3). (C) Immunoblot
of PARP cleavage in MCF-7 and MDA-MB-231 cells treated with
LY294002.indicated by decreased p-Akt1 levels. MCF-7 cell viabil-
ity declined upon LY294002 treatment (Figure 6B), and
this was the result of apoptosis as indicated by increased
PARP cleavage (Figure 6C). In contrast, MDA-MB-231
cell viability was unaffected by LY294002 treatment.
These data indicate that MCF-7 cells are more
dependent on PI3K/Akt1 pro-survival signaling than
MDA-MB-231 cells, and are in agreement with previous
reports showing a differential requirement for PI3K sig-
naling in these two cell lines [19,20].
Constitutively active Akt1 partially rescues MP1 siRNA
induced apoptosis of MCF-7 cells
MP1 silencing resulted in decreased Akt1 activity in
MCF-7 cells, which are highly dependent on pro-
survival signals from the PI3K/Akt pathway (Figure 6).
To examine whether active Akt1 is sufficient to maintain
cell viability in the absence of MP1, we generated MCF-
7 cells expressing constitutively active Akt1 (MCF-7/
Myr-Flag-Akt1). Phosphorylated-Akt1 (p-Akt) was
highly expressed in a pool of MCF-7/Myr-Flag-Akt1
cells compared to a pool of cells containing the control
pBabe-puro vector (Figure 7A). These two pools of cells
were transfected with MP1 siRNA or control siRNA,
and the effects on cell survival were examined. As shown
in Figure 7B, 64% of pBabe-puro containing cells were
dead in the MP1 siRNA treated sample, but this
decreased to 41% in cells expressing constitutively active
Akt1. The extent of PARP cleavage in response to MP1
silencing was also decreased in Myr-Flag-Akt1 expres-
sing cells relative to the control cell line (Figure 7C).
These experiments were repeated with clonal transfec-
tants containing control vector or Myr-Flag-Akt1 with
similar results (Additional file 1: Figure S1). Together,
these findings indicate that expression of active Akt1
partially overcomes the requirement for MP1 expression
for survival of MCF-7 cells. As shown in Figure 7C, ex-
pression of Myr-Flag-Akt1 also rescued the decrease in
ER levels that is seen upon MP1silencing. However, this
might not be critical to its effect since the results shown
in Figure 5 indicate that decreased ER expression does
not result in apoptosis.
Discussion
The results presented here reveal a novel role for the
small scaffold protein MP1 in ER-positive breast cancer
cells. Although MP1 is expressed in both ER-positive
and ER-negative breast cancer cells, its depletion using
RNAi-mediated gene silencing leads to detachment and
death of several ER-positive cell lines, including one
(LCC9) with acquired estrogen independence and anties-
trogen resistance. In contrast, MP1 gene silencing had
no detectable effect in three ER-negative breast cancer







































siRNA CON   MP1 CON   MP1
PARP
% PARP cleaved   24     71 25     31         
ER
Figure 7 Constitutively active Akt1 partially rescues MCF-7 cells from apoptosis induced by MP1 gene silencing. (A) Immunoblot of p-
Akt and Flag in stable pools of MCF-7 cells infected with control (pBabe-puro) or Myr-Flag-Akt1 expression vector as described in Materials and
Methods. (B) The stable pools of cells described in (A) were transfected with 30 nM control siRNA or MP1 siRNA for 48 h, and cell viability was
determined by trypan blue exclusion assay. Bars represent the percentage of trypan blue-positive cells. Error bars represent the mean ± SD for
three independent experiments, *p< 0.05. (C) Immunoblot of PARP, ER and MP1 in a representative experiment described in (B).
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been depleted in rat fibroblasts and human prostate can-
cer cells, and cell detachment or death was not reported
in either case [7,8]. Therefore, MP1 expression seems to
be required for survival in a subset of cell types, includ-
ing ER-positive breast cancer cells. The mechanism of
cell death that occurs as a result of inhibiting MP1 ex-
pression in MCF-7 cells was shown to be apoptosis, as
demonstrated by decreased Bcl-2 expression, increased
PARP cleavage, Annexin V staining, and rescue of the
death phenotype by treatment with the pan-caspase in-
hibitor z-VAD-FMK.
Several interesting questions are raised by these
results. One is what pro-survival pathways are affected
by loss of MP1 expression in MCF-7 cells. Depletion of
MP1 did not result in decreased ERK activation, indicat-
ing that its pro-survival functions are not mediated by
the ERK pathway. The lack of an effect on ERK activitywas somewhat surprising, since MP1 was originally iden-
tified as a scaffold protein that increases ERK signaling
[1], but is consistent with results obtained in prostate
cancer cells [8]. In contrast, inhibition of MP1 expres-
sion resulted in a greater than two fold decrease in Akt
phosphorylation. The extent of Akt inhibition may be an
underestimate, since by 48 h a majority of cells were
dead, and the remaining live cells might represent ones
with the lowest extent of MP1 knockdown. Akt plays a
known pro-survival function in breast cancer cells,
where it relays signals from upstream molecules includ-
ing integrins, growth factor receptors, PI3K and
mTORC1 to downstream molecules such as Bcl-2 and
NF-κB [21-26]. In MCF-7 cells, the activity of Akt1 can
be modulated by estradiol and IGF [27-29]. The fact that
this kinase likely also plays a role in MP1 mediated sur-
vival is supported by the fact that expression of a consti-
tutively active Akt1 partially rescued the cell death
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the partial effect observed indicates that there are likely
to be additional survival pathways involved as well.
Depletion of MP1 in MCF-7 cells also resulted in
decreased levels of ERα protein, mRNA (data not
shown) and transcriptional activity on ERE-containing
promoters. The apoptosis observed is unlikely to be due
solely to a loss of ER signaling, since we and others have
found that inhibition of ER expression using siRNA does
not result in MCF-7 cell death [30]. The fact that LCC9
cells, which are estrogen independent and antiestrogen
resistant, die in response to MP1 gene silencing also
supports a model in which loss of ER expression is not
the sole cause of cell death. Several studies indicate that
ER may be implicated in breast cancer cell survival via
cross-talk with the PI3K/Akt pathway [31], or by regulat-
ing the activity of NF-κB [32,33], Bcl-2 [34,35], or IAP
family members [36]. We therefore cannot rule out the
possibility that decreased ER expression may contribute
in some way to the apoptosis observed in MCF-7 cells.
A second question raised by these results is the mo-
lecular basis for the differential requirement for MP1 for
survival of ER-positive vs. ER-negative breast cancer
cells. One possibility is that activation of pro-survival
proteins such as Akt is not dependent on MP1 in ER-
negative cells, and a second is that the ER-negative cells
are less dependent on these pro-survival signaling path-
ways. The fact that LY294002 caused a concentration-
dependent apoptotic response in MCF-7 cells, but did
not affect MDA-MB-231 cells supports the latter hy-
pothesis. This is in agreement with previous reports de-
scribing a differential sensitivity to this compound
between the two breast cancer cell lines [19,20].
A final question is whether the cell death that we have
observed is related to the previously identified roles of
MP1 in cell spreading and motility. Since the phenotype
involves cell rounding and detachment, inhibition of
MP1expression may disrupt cell adhesion signals, which
could then trigger cell death. Preliminary PCR array
experiments indicated that inhibiting MP1 expression
leads to decreased expression of molecules involved in
cell adhesion in MCF-7 cells, including several integrins
(data not shown). Immunoblotting analysis indicated a
small but reproducible decrease in beta 1 integrin pro-
tein levels upon MP1 silencing (Additional file 2: Figure
S2). Since integrins can initiate pro-survival signaling
[37], future experiments will investigate if a loss of integ-
rin expression plays a role in the decreased Akt activa-
tion and/or apoptosis observed as a result of MP1
knockdown.
Conclusions
This is the first report investigating the role of the small
scaffold protein MP1 in breast cancer cells. We havedemonstrated that inhibiting MP1 protein expression
results in apoptosis in ER-positive breast cancer cells,
but not ER-negative breast cancer or non-tumorigenic
mammary epithelial cells. Furthermore, MP1 gene silen-
cing led to decreased Akt activity in ER-positive MCF-7
cells, these cells are highly dependent upon the Akt
pathway for survival, and expression of a constitutively
active form of Akt partially rescued cells from apoptosis.
We therefore hypothesize that MP1 is required for pro-
survival signaling mediated by Akt, and that it may pro-
vide a novel target for the treatment of ER-positive
breast cancers, including those (such as LCC9) with
acquired endocrine resistance.
Methods
Cell lines and culture conditions
MCF-7 and LCC9 cells were obtained from the Lom-
bardi Cancer Center. T47D, ZR-75-1, MDA-MB-231,
BT-549, and Sk-Br-3 cells were purchased from the
American Type Culture Collection. Cells were main-
tained in Improved Modified Eagle’s Medium (IMEM)
containing phenol red (GIBCO-Invitrogen-Applied Bio-
systems), supplemented with 5% fetal bovine serum
(HyClone), and 100 Units/ml Penicillin/100 μg/ml
Streptomycin (Invitrogen) and incubated at 37°C with
5% CO2.
siRNA transfections
All siRNA transfection reagents were purchased from
Dharmacon-Thermo Scientific. Two independent MP1
siRNA duplexes (ON-TARGETplus), a non-targeting
siRNA (ON-TARGETplus siCONTROL) and an ER siRNA
(ON-TARGETplus) were used. Cells were plated in six-
well plates at 105 to 3 x 105 cells per well in FBS con-
taining medium. After 24 h, cells were transfected with
30–150 nM of either control or MP1 siRNA using
DharmaFECT 1 transfection reagent. For MP1 siRNA
and ER siRNA cotransfection cells were treated with a 30
nM mix of two duplexes. Cells were harvested after 24 or
48 h, then lysed in CelLytic M lysis buffer (Sigma), supple-
mented with cocktail tablets of protease (Roche -
Complete Mini EDTA-free) and phosphatase inhibitors
(Roche – PhosSTOP).
Determination of cell death
Cell death was assessed at 48 h post transfection using
Trypan blue exclusion assays. Briefly, floating cells were
collected, centrifuged, and resuspended in PBS, while
attached cells were trypsinized, centrifuged, and resus-
pended in PBS. For each cell suspension, 18 μl were incu-
bated with 2 μl trypan blue for 15 min and both total
number and the number of dead cells were counted with a
hemacytometer. The remaining harvested cells were pro-
cessed for protein determination and immunoblotting.
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MCF-7 cells were cultured in six-well plates at 3 x 105
cells per well. The following day they were co-
transfected with 0.5 μg of ERE2-tk109-luc and 0.06 μg of
pβgal-Basic, using Superfect transfection reagent from
Qiagen. After 3 h, the medium was changed to transfec-
tion mixes containing either control or MP1 siRNA and
cells were incubated overnight. The transfection medium
was then replaced with phenol red-free IMEM supple-
mented with 5% charcoal stripped serum (CSS) for 24 h,
then cells were stimulated with 10 nM 17β-estradiol
(Sigma) for 8 h. Cells were lysed and assayed for lucifer-
ase (Promega) and β-galactosidase (Clonetech) activity
as suggested by each manufacturer.
Immunoblotting
Protein concentrations were determined using the Brad-
ford protein assay (Bio-Rad). Total protein (10–20 μg)
was subjected to 4-20% Tris–HCl SDS-PAGE (Bio-Rad),
transferred to Immobilon-FL polyvinylidene difluoride
membranes (Millipore), blocked with Odyssey Blocking
Buffer and then incubated with the appropriate primary
antibodies. Alexa Fluor 680 anti-goat and anti-rabbit
(Invitrogen) and IRDye 800CW anti-mouse (LI-COR)
secondary antibodies were used for two-color detection
of proteins. Membranes were scanned and analyzed
using the LI-COR Odyssey system.
Antibodies and reagents
The following primary antibodies were used for Western
blotting: MP1 (A-19, Santa Cruz), actin (AC-40,
SIGMA), estrogen receptor alpha (AB-17, Lab Vision-
Thermo Scientific, or F-10, Santa Cruz), PARP (Cell Sig-
naling), p-AKT (T308, Cell Signaling), AKT1 (BDI111,
Santa Cruz), ERK (C-16, Santa Cruz), p-ERK (Cell Sig-
naling), Flag M2 (Sigma), or Bcl-2 (BD Biosciences). Pan
caspase inhibitor z-VAD-FMK was obtained from BD
Biosciences and PI3K inhibitor LY294002 was purchased
from Sigma.
Retroviral infection of MCF-7 cells
pBabe-puro (Addgene plasmid 1764) or pBabe-puro-
Myr-Flag-AKT1 (Addgene plasmid 15294, [38]) were
transfected into 293GPG packaging cells and retroviral
stocks were prepared as previously described [39]. These
virus stocks were used to infect MCF-7 cells (1 ml per
10 cm dish), in the presence of polybrene (8 μg/ml), and
stable colonies were selected with 0.5 μg/ml puromycin.
Both single colonies and pools of 50–100 colonies were
selected and propagated. Stable cell lines/pools were
routinely maintained in medium supplemented with
0.25 μg/ml puromycin and plated in puromycin-free
conditions for siRNA transfections.Annexin V staining
Forty eight hours post transfection, floating and attached
cells were collected, pooled, washed with PBS, and then
prepared for annexin V-FITC and propidium iodide
staining according to the manufacturer’s instructions
(556547, BD Biosciences). Cells resuspended in 500 μl
annexin V binding buffer were analyzed by flow cytome-
try using a FACSVantage SE system (BD Biosciences)
and analyzed using the FlowJo software.Gene expression analysis
To examine gene expression across human breast cancer
samples, the following 8 breast cancer datasets were
downloaded from GEO: GSE2034, GSE3494, GSE6532,
GSE4922, GSE11121, GSE7390, GSE2603 and GSE14020.
Data was normalized using RMA in the Affymetrix Ex-
pression console. The eight datasets were then combined,
and batch effects were removed using the BFRM algo-
rithm (Yuwanita and Andrechek, Unpublished). MP1 ex-
pression was examined in the resulting combined dataset
within the various clinical parameters associated with the
datasets, including ER and PR status, time to distant metas-
tasis, and disease free survival. In addition, ER / PR status
was predicted using genomic signatures as previously
described [15], and MP1 expression levels were compared
in hormone receptor positive vs. negative cells. In all cases,
p values were calculated using an unpaired two tailed t test.Statistical analysis
Data are expressed as the mean ± S.D. Experiments were
performed three times unless otherwise indicated. Paired
evaluations were made for experimental and control
conditions within each set of experiments. For compar-
ing groups of cell lines, an unpaired two-tailed evalu-
ation was done. Significance was determined by
Student’s t test. Significance level was set at p< 0.05.Additional files
Additional file 1: Constitutively active Akt1 partially rescues MCF-7
cells from the apoptosis induced by MP1 siRNA. (A) Immunoblots of
total and p-Akt in individual clones of MCF-7 cells infected with control
(pBabe-puro) or Myr-Flag-Akt1 expression vector as described in Materials
and Methods. The pBabe control-expressing clones did not have
detectable levels of p-Akt. The stable clone #1 of control (pBabe-puro)
and clone #2 of Myr-Flag-Akt1 expressing cells described in (A) were
transfected with 30 nM control siRNA or MP1 siRNA for 48 h. (B)
Immunoblot of MP1. (C) Trypan blue exclusion assay.
Additional file 2: Effect of MP1 knockdown on β1 integrin protein
expression in MCF-7 and MDA-MB-231 cells. Immunoblot of β1
integrin. Anti β1 integrin antibody N-20 from Santa Cruz was used
(n = 3 ± SD, p> 0.1).Competing interests
The authors declare that they have no competing interests.
Marina et al. Cell Communication and Signaling 2012, 10:18 Page 11 of 12
http://www.biosignaling.com/content/10/1/18Acknowledgements
The authors would like to thank Dr. Eran Andrechek and Ms. Inez Yuwanita
for assistance with the analysis of gene expression datasets. We also thank
Ms. Chotirat Rattanasinchai for assistance with experiments. Finally, we thank
Dr. Robert Clarke for providing LCC9 cells. This research was supported by
IDEA Grant W81XWH-07-1-0500 from the Department of Defense Breast
Cancer Research Program, and by the Jean P. Schultz Endowed Oncology
Research Fund in the College of Human Medicine.
Author details
1Department of Physiology, Michigan State University, East Lansing, MI
48824, USA. 2Current address: Department of Radiation Oncology, Winship
Cancer Institute, Atlanta, GA 30322, USA. 3Department of Microbiology and
Molecular Genetics, Michigan State University, East Lansing, MI 48864, USA.
Authors’ contributions
MM designed and conducted experiments, analyzed data and jointly wrote
the manuscript. LW designed and conducted apoptosis and flow cytometry
experiments, and reviewed the manuscript. SEC conceived of the study,
designed experiments, analyzed data and jointly wrote the manuscript. All
authors read and approved the final manuscript.
Received: 6 February 2012 Accepted: 9 July 2012
Published: 9 July 2012
References
1. Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ: MP1: a
MEK binding partner that enhances enzymatic activation of the MAP
kinase cascade. Science 1998, 281:1668–1671.
2. Teis D, Taub N, Kurzbauer R, Hilber D, de Araujo ME, Erlacher M,
Offterdinger M, Villunger A, Geley S, Bohn G, et al: p14-MP1-MEK1
signaling regulates endosomal traffic and cellular proliferation during
tissue homeostasis. J Cell Biol 2006, 175:861–868.
3. Teis D, Wunderlich W, Huber LA: Localization of the MP1-MAPK scaffold
complex to endosomes is mediated by p14 and required for signal
transduction. Dev Cell 2002, 3:803–814.
4. Pullikuth AK, Catling AD: Scaffold mediated regulation of MAPK signaling
and cytoskeletal dynamics: a perspective. Cell Signal 2007, 19:1621–1632.
5. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM:
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is
necessary for its activation by amino acids. Cell 2010, 141:290–303.
6. Park ER, Eblen ST, Catling AD: MEK1 activation by PAK: a novel
mechanism. Cell Signal 2007, 19:1488–1496.
7. Pullikuth A, McKinnon E, Schaeffer HJ, Catling AD: The MEK1 scaffolding
protein MP1 regulates cell spreading by integrating PAK1 and Rho
signals. Mol Cell Biol 2005, 25:5119–5133.
8. Park ER, Pullikuth AK, Bailey EM, Mercante DE, Catling AD: Differential
requirement for MEK Partner 1 in DU145 prostate cancer cell migration.
Cell Commun Signal 2009, 7:26.
9. Mouchel-Vielh E, Bloyer S, Salvaing J, Randsholt NB, Peronnet F:
Involvement of the MP1 scaffold protein in ERK signaling regulation
during Drosophila wing development. Genes Cells 2008, 13:1099–1111.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
11. Russo IH, Russo J: Role of hormones in mammary cancer initiation and
progression. J Mammary Gland Biol Neoplasia 1998, 3:49–61.
12. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R:
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2
/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004,
96:926–935.
13. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R: P21-activated kinase-1
phosphorylates and transactivates estrogen receptor-alpha and
promotes hyperplasia in mammary epithelium. EMBO J 2002,
21:5437–5447.
14. Yamnik RL, Holz MK: mTOR/S6K1 and MAPK/RSK signaling pathways
coordinately regulate estrogen receptor alpha serine 167
phosphorylation. FEBS Lett 2010, 584:124–128.
15. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB,
Kelley M, Mathey-Prevot B, Potti A, Nevins JR: A pathway-based
classification of human breast cancer. Proc Natl Acad Sci U S A 2010,
107:6994–6999.16. Veer LJ van 't, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse
HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression
profiling predicts clinical outcome of breast cancer. Nature 2002,
415:530–536.
17. Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen
T, Spang-Thomsen M, Fuqua SA, Clarke R: MCF7/LCC9: an antiestrogen-
resistant MCF-7 variant in which acquired resistance to the steroidal
antiestrogen ICI 182,780 confers an early cross-resistance to the
nonsteroidal antiestrogen tamoxifen. Cancer Res 1997, 57:3486–3493.
18. Stampfer MR, Bartley JC: Induction of transformation and continuous cell
lines from normal human mammary epithelial cells after exposure to
benzo[a]pyrene. Proc Natl Acad Sci U S A 1985, 82:2394–2398.
19. Bartucci M, Morelli C, Mauro L, Ando S, Surmacz E: Differential insulin-like
growth factor I receptor signaling and function in estrogen receptor
(ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Cancer Res 2001, 61:6747–6754.
20. Clark AS, West K, Streicher S, Dennis PA: Constitutive and inducible Akt
activity promotes resistance to chemotherapy, trastuzumab, or
tamoxifen in breast cancer cells. Mol Cancer Ther 2002, 1:707–717.
21. Bratton MR, Duong BN, Elliott S, Weldon CB, Beckman BS, McLachlan JA,
Burow ME: Regulation of ERalpha-mediated transcription of Bcl-2 by
PI3K-AKT crosstalk: implications for breast cancer cell survival. Int J Oncol
2010, 37:541–550.
22. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A,
Sasaki AT, Thomas G, Kozma SC, et al: Inhibition of mTORC1 leads to
MAPK pathway activation through a PI3K-dependent feedback loop in
human cancer. J Clin Invest 2008, 118:3065–3074.
23. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV: Akt phosphorylates and
negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol
2001, 21:893–901.
24. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell
2007, 129:1261–1274.
25. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR: Glycogen
synthase kinase-3 regulates mitochondrial outer membrane
permeabilization and apoptosis by destabilization of MCL-1. Mol Cell
2006, 21:749–760.
26. Nam JM, Onodera Y, Bissell MJ, Park CC: Breast cancer cells in three-
dimensional culture display an enhanced radioresponse after coordinate
targeting of integrin alpha5beta1 and fibronectin. Cancer Res 2010,
70:5238–5248.
27. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi
M, Fiorentino R, Varricchio L, Barone MV, Auricchio F: PI3-kinase in concert
with Src promotes the S-phase entry of oestradiol-stimulated MCF-7
cells. EMBO J 2001, 20:6050–6059.
28. Ahmad S, Singh N, Glazer RI: Role of AKT1 in 17beta-estradiol- and
insulin-like growth factor I (IGF-I)-dependent proliferation and
prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem
Pharmacol 1999, 58:425–430.
29. Lee YR, Park J, Yu HN, Kim JS, Youn HJ, Jung SH: Up-regulation of PI3K/
Akt signaling by 17beta-estradiol through activation of estrogen
receptor-alpha, but not estrogen receptor-beta, and stimulates cell
growth in breast cancer cells. Biochem Biophys Res Commun 2005,
336:1221–1226.
30. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D,
Sonenshein GE: Oestrogen signalling inhibits invasive phenotype by
repressing RelB and its target BCL2. Nat Cell Biol 2007, 9:470–478.
31. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri
H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen
receptor alpha: a new model for anti-estrogen resistance. J Biol Chem
2001, 276:9817–9824.
32. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY, Stanculescu A:
Positive cross-talk between estrogen receptor and NF-kappaB in breast
cancer. Cancer Res 2009, 69:8918–8925.
33. Riggins RB, Zwart A, Nehra R, Clarke R: The nuclear factor kappa B
inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-
induced apoptosis in antiestrogen-resistant breast cancer cells. Mol
Cancer Ther 2005, 4:33–41.
34. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde
MP, Vyhlidal C, Safe S: Mechanisms of transcriptional activation of bcl-2
gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem
1999, 274:32099–32107.
Marina et al. Cell Communication and Signaling 2012, 10:18 Page 12 of 12
http://www.biosignaling.com/content/10/1/1835. Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemotherapeutic drug
resistance by a mechanism involving Bcl-2 proto-oncogene expression
in human breast cancer cells. Cancer Res 1995, 55:3902–3907.
36. Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, Frasor J:
Estrogen promotes breast cancer cell survival in an Inhibitor of
Apoptosis (IAP)-dependent manner. Horm Cancer 2010, 1:127–135.
37. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ:
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer
cells, inhibits growth, and distinguishes malignant from normal
phenotype in three dimensional cultures and in vivo. Cancer Res 2006,
66:1526–1535.
38. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK,
Garraway LA, Weremowicz S, Richardson AL, et al: Integrative genomic
approaches identify IKBKE as a breast cancer oncogene. Cell 2007,
129:1065–1079.
39. Ory DS, Neugeboren BA, Mulligan RC: A stable human-derived packaging
cell line for production of high titer retrovirus/vesicular stomatitis virus
G pseudotypes. Proc Natl Acad Sci U S A 1996, 93:11400–11406.
doi:10.1186/1478-811X-10-18
Cite this article as: Marina et al.: The scaffold protein MEK Partner 1 is
required for the survival of estrogen receptor positive breast cancer
cells. Cell Communication and Signaling 2012 10:18.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
